This translates into more than a 1,300-fold reduction in CD33+CD34− FLT3D/Y AML cells in TCRFLT3D/Y-treated mice (Fig. 4d,e, Extended Data Fig. 9c and Supplementary Table 8). This evidence concerns the gene CD33 and acute myeloid leukemia.